Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary care.

Able SL, Robinson RL, Kroenke K, Mease P, Williams DA, Chen Y, Wohlreich M, McCarberg BH.

Pragmat Obs Res. 2016 May 20;7:11-20. eCollection 2016.

2.

Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials.

Tokuoka H, Takahashi H, Ozeki A, Kuga A, Yoshikawa A, Tsuji T, Wohlreich MM.

J Affect Disord. 2016 May 15;196:171-80. doi: 10.1016/j.jad.2016.02.039. Epub 2016 Feb 17.

3.

Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trials.

Harada E, Tokuoka H, Fujikoshi S, Funai J, Wohlreich MM, Ossipov MH, Iwata N.

Pain. 2016 Mar;157(3):577-84. doi: 10.1097/j.pain.0000000000000406.

4.

Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.

Harada E, Kato M, Fujikoshi S, Wohlreich MM, Berggren L, Tokuoka H.

Int J Clin Pract. 2015 Oct;69(10):1139-48. doi: 10.1111/ijcp.12658. Epub 2015 May 16.

5.

Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials.

Williamson OD, Schroer M, Ruff DD, Ahl J, Margherita A, Sagman D, Wohlreich MM.

Clin Ther. 2014 Apr 1;36(4):544-51. doi: 10.1016/j.clinthera.2014.02.009. Epub 2014 Mar 17.

PMID:
24650448
6.

Long-term evaluation of opioid treatment in fibromyalgia.

Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, Faries D, Wohlreich M, McCarberg B, Hann D.

Clin J Pain. 2015 Jan;31(1):7-13. doi: 10.1097/AJP.0000000000000079.

PMID:
24480913
7.

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective-author response to letter to the editor.

Wielage RC, Bansal M, Scott Andrews J, Wohlreich MM, Klein RW, Happich M.

Value Health. 2013 Dec;16(8):1173-4. doi: 10.1016/j.jval.2013.09.005. No abstract available.

8.

Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study.

Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, Peng X, Hann D, Wohlreich M, McCarberg B.

Pain Med. 2013 Sep;14(9):1400-15. doi: 10.1111/pme.12168. Epub 2013 Jun 11.

9.

Duloxetine dose escalation in patients with osteoarthritis knee pain, who were taking optimized NSAIDs.

Wohlreich M, Frakes E, Risser RC, Ahl J.

Curr Med Res Opin. 2013 Aug;29(8):879. doi: 10.1185/03007995.2013.806889. Epub 2013 Jun 5. No abstract available.

PMID:
23692264
10.
11.

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M.

Value Health. 2013 Mar-Apr;16(2):334-44. doi: 10.1016/j.jval.2012.12.006.

12.

Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.

Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.

Pain Pract. 2014 Jan;14(1):22-31. doi: 10.1111/papr.12044. Epub 2013 Mar 14.

PMID:
23489659
13.

Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions.

Gaynor PJ, Liu P, Weller MA, Wohlreich MM.

Curr Med Res Opin. 2013 May;29(5):549-60. doi: 10.1185/03007995.2013.784191. Epub 2013 Apr 3.

PMID:
23477538
14.

Burden of illness and treatment patterns for patients with fibromyalgia.

Robinson RL, Kroenke K, Mease P, Williams DA, Chen Y, D'Souza D, Wohlreich M, McCarberg B.

Pain Med. 2012 Oct;13(10):1366-76. doi: 10.1111/j.1526-4637.2012.01475.x. Epub 2012 Sep 7.

PMID:
22958298
15.

The effect of duloxetine treatment on cognition in patients with fibromyalgia.

Mohs R, Mease P, Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM.

Psychosom Med. 2012 Jul-Aug;74(6):628-34. doi: 10.1097/PSY.0b013e31825b9855. Epub 2012 Jun 28.

PMID:
22753629
16.

Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis.

Hochberg MC, Wohlreich M, Gaynor P, Hanna S, Risser R.

J Rheumatol. 2012 Feb;39(2):352-8. doi: 10.3899/jrheum.110307. Epub 2011 Dec 1.

PMID:
22133624
17.

Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial.

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM.

Curr Med Res Opin. 2011 Dec;27(12):2361-72. doi: 10.1185/03007995.2011.633502. Epub 2011 Nov 9. Erratum in: Curr Med Res Opin. 2012 May;28(5):822.

PMID:
22017192
18.
19.

Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.

Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM.

J Rheumatol. 2010 Dec;37(12):2578-86. doi: 10.3899/jrheum.100365. Epub 2010 Sep 15.

PMID:
20843911
20.

Effect of duloxetine in patients with fibromyalgia: tiredness subgroups.

Bradley LA, Bennett R, Russell IJ, Wohlreich MM, Chappell AS, Wang F, D'Souza DN, Moldofsky H.

Arthritis Res Ther. 2010;12(4):R141. doi: 10.1186/ar3081. Epub 2010 Jul 14.

21.

Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.

Marangell LB, Clauw DJ, Choy E, Wang F, Shoemaker S, Bradley L, Mease P, Wohlreich MM.

Pain. 2011 Jan;152(1):31-7. doi: 10.1016/j.pain.2010.05.029. Epub 2010 Jul 2.

PMID:
20598442
22.

Pain response profile of patients with fibromyalgia treated with duloxetine.

Bradley LA, Wohlreich MM, Wang F, Gaynor PJ, Robinson MJ, D'Souza DN, Mease PJ.

Clin J Pain. 2010 Jul-Aug;26(6):498-504. doi: 10.1097/AJP.0b013e3181dee80e.

PMID:
20551724
23.

Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.

Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, Chappell AS.

Prim Care Companion J Clin Psychiatry. 2009;11(5):237-44. doi: 10.4088/PCC.08m00680.

24.

What makes patients with fibromyalgia feel better? Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine.

Hudson JI, Arnold LM, Bradley LA, Choy EH, Mease PJ, Wang F, Ahl J, Wohlreich MM.

J Rheumatol. 2009 Nov;36(11):2517-22. doi: 10.3899/jrheum.090139. Epub 2009 Oct 15.

PMID:
19833743
25.

Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.

Wohlreich MM, Sullivan MD, Mallinckrodt CH, Chappell AS, Oakes TM, Watkin JG, Raskin J.

Psychosomatics. 2009 Jul-Aug;50(4):402-12. doi: 10.1176/appi.psy.50.4.402.

PMID:
19687181
26.

Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.

Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.

Clin J Pain. 2009 Jul-Aug;25(6):461-8. doi: 10.1097/AJP.0b013e318197d4e4.

PMID:
19542792
27.

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.

Choy EH, Mease PJ, Kajdasz DK, Wohlreich MM, Crits-Christoph P, Walker DJ, Chappell AS.

Clin Rheumatol. 2009 Sep;28(9):1035-44. doi: 10.1007/s10067-009-1203-2. Epub 2009 Jun 18.

28.

A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.

Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH.

J Clin Psychiatry. 2008 Sep;69(9):1383-92.

PMID:
19193339
29.

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.

Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS.

Semin Arthritis Rheum. 2010 Jun;39(6):454-64. doi: 10.1016/j.semarthrit.2008.11.001. Epub 2009 Jan 18.

PMID:
19152958
30.

Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.

Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M.

Ann Clin Psychiatry. 2008 Oct-Dec;20(4):209-18. doi: 10.1080/10401230802437639.

PMID:
19034753
31.

The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.

Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlreich MM.

Ann Clin Psychiatry. 2008 Oct-Dec;20(4):187-93. doi: 10.1080/10401230802435609.

PMID:
19034749
32.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
33.

Implications of pain in generalized anxiety disorder: efficacy of duloxetine.

Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, Perahia DG, Erickson JS.

Prim Care Companion J Clin Psychiatry. 2008;10(3):197-204.

34.

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.

Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J.

Hum Psychopharmacol. 2008 Aug;23(6):519-26. doi: 10.1002/hup.949.

PMID:
18478624
35.

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM.

Pain. 2008 Jun;136(3):432-44. doi: 10.1016/j.pain.2008.02.024. Epub 2008 Apr 18.

PMID:
18395345
36.

Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial.

Petersen T, Perlis RH, Ticknor C, Lohr J, Solvason HB, O'Reardon JP, Wohlreich MM, Andreotti C, Wilson M, Fava M.

Psychopharmacol Bull. 2008;41(1):34-45.

PMID:
18362869
37.

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH.

J Clin Psychiatry. 2007 Dec;68(12):1921-30.

PMID:
18162024
38.

Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study.

Wohlreich MM, Wiltse CG, Desaiah D, Ye W, Robinson RL, Kroenke K, Kornstein SG, Greist JH.

Prim Care Companion J Clin Psychiatry. 2007;9(4):271-9.

39.

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.

Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ.

Int Clin Psychopharmacol. 2007 Nov;22(6):348-55.

PMID:
17917553
40.

The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.

Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM.

Ann Clin Psychiatry. 2007 Jul-Sep;19(3):187-95.

PMID:
17729021
41.

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.

Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M.

J Sex Med. 2007 Jul;4(4 Pt 1):917-29.

PMID:
17627739
42.

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.

Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.

Int J Clin Pract. 2007 Aug;61(8):1337-48. Review.

PMID:
17627710
43.

Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.

Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M.

Depress Anxiety. 2008;25(5):E1-8.

PMID:
17621644
44.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
45.

Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine.

Moore HK, Wohlreich MM, Wilson MG, Mundt JC, Fava M, Mallinckrodt CH, Greist JH.

Psychiatry (Edgmont). 2007 Mar;4(3):30-8.

46.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
47.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.

Lewis-Fernández R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM.

J Clin Psychiatry. 2006 Sep;67(9):1379-90.

PMID:
17017824
48.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
49.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
50.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.

J Affect Disord. 2006 Aug;94(1-3):183-9. Epub 2006 Jun 14.

PMID:
16780958

Supplemental Content

Loading ...
Support Center